Dive into the archives.
- What’s the Point of Extavia?
Featured Story Oct. 16, 2009
By Angela Maas, Managing Editor
Another drug in the self-injected multiple sclerosis (MS) class recently came onto the marketplace. But many within the pharmaceutical industry are saying that other than giving Novartis an entry into the MS market before its [...]
- Novartis says FTY720 reduces relapses
ZURICH, Sept 30 (Reuters) – Swiss drugmaker Novartis AG said on Wednesday its FTY720 oral drug to treat multiple sclerosis reduced both relapses and disability progression.
Initial results from the two-year Phase III study show that oral FTY720 was significantly superior to placebo in reducing both relapses and disability progression in patients with relapsing-remitting multiple sclerosis, [...]
- Novartis MS drug linked to new side effect
LONDON, April 14 — Fresh side-effect problems have emerged with Novartis AG’s experimental oral multiple sclerosis (MS) drug FTY720, with doctors reporting a case of haemorrhaging focal encephalitis.
A case report on the patient who developed the condition after taking part in a Phase III clinical trial of the medicine — one of the big hopes [...]
